Ray Dalio
CORT icon

Ray Dalio’s Corcept Therapeutics CORT Stock Holding History

Ray Dalio’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.55M Sell
38,422
-240,578
-86% -$9M 0.01% 708
2025
Q4 		$9.71M Sell
279,000
-26,946
-9% -$2.12M 0.04% 364
2025
Q3 		$25.4M Buy
+305,946
New +$22.1M 0.1% 169

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Ray Dalio's CORT Position: Q1 2026 in Review

Ray Dalio reduced its Corcept Therapeutics (CORT) stake by 86% in Q1 2026, selling an estimated $9M and leaving 38,422 shares worth $1.55M. The position accounts for 0.01% of the portfolio, ranked #708.

Ray Dalio first reported a position in CORT in Q3 2025 and has held it in 3 quarters since. The position peaked at $25.4M in Q3 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Ray Dalio held 38,422 shares of Corcept Therapeutics worth $1.55M as of Q1 2026.
  • Ray Dalio sold 240,578 Corcept Therapeutics shares in Q1 2026, an estimated $9M.
  • Corcept Therapeutics made up 0.01% of Ray Dalio's portfolio in Q1 2026, its #708 holding.
  • Ray Dalio first reported a position in Corcept Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Ray Dalio's Corcept Therapeutics position peaked at $25.4M in Q3 2025.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.